-
Mashup Score: 0
The median OS was 18.5 months in those who received 6 or more cycles of induction chemotherapy vs 13.1 months in those who did not.
Source: www.cancernetwork.comCategories: General Medicine NewsTweet
The median OS was 18.5 months in those who received 6 or more cycles of induction chemotherapy vs 13.1 months in those who did not.
6 or more cycles of induction chemotherapy led to significantly prolonged PFS and OS, enhancing the efficacy of first-line atezolizumab combined with chemotherapy in patients with ES-SCLC. #lcsm #SCLC #RadOnc https://t.co/qsF49LO46l